FDA product code QFG: Alternate Controller Enabled Insulin Infusion Pump

QFG is the FDA product code for alternate controller enabled insulin infusion pump. It is a Class II device, regulated under 21 CFR 880.5730 and reviewed by the Clinical Chemistry panel. FDA has cleared 29 510(k) submissions under QFG, 27 in the last five years, from 9 different applicants. The average 510(k) review took 165 days (median 97); 94 days on average over the last three years. 1 De Novo request was granted under it. FDA has posted 24 recalls for QFG devices, 24 initiated in the last five years.

Definition

An alternate controller enabled insulin infusion pump (ACE insulin pump) is a device intended for the infusion of insulin into a patient. The ACE insulin pump may include basal and bolus drug delivery at set or variable rates. ACE insulin pumps are designed to reliably and securely communicate with external devices, such as automated insulin dosing systems, to allow insulin delivery commands to be received, executed, and confirmed. ACE insulin pumps are intended to be used both alone and in conjunction with digitally connected medical devices for the purpose of insulin delivery.

Classification

FieldValue
Device nameAlternate Controller Enabled Insulin Infusion Pump
Device classClass II
Regulation21 CFR 880.5730
Review panelCH — Clinical Chemistry
Medical specialtyClinical Chemistry
Premarket route510(k)

510(k) clearances per year for QFG

YearClearancesAvg. review days
2019188
2020130
20222434
20239252
20245103
2025572
20266108

Compare with all 510(k) review times · Search every QFG clearance

Top QFG applicants

ApplicantClearancesLatest
Tandem Diabetes Care, Inc.92025-11-06
Beta Bionics, Inc.62026-10-21
Deka Research and Development42026-06-17
Medtronic Minimed, Inc.32026-03-12
Insulet Corporation32023-10-18

4 more applicants have QFG clearances. See the full list in Caduvo.

Most recent QFG clearances

510(k)ApplicantDeviceDecision dateReview days
K263422Beta Bionics, Inc.Mint ACE Pump2026-10-2126
K260001Beta Bionics, Inc.Mint ACE Pump2026-09-11252
K261672Deka Research and Developmenttwiist Automated Insulin Delivery (AID) System2026-06-1727
K253976Beta Bionics, Inc.iLet ACE Pump2026-04-30139
K253743Medtronic Minimed, Inc.MiniMed Flex pump2026-03-12108

Recalls for QFG devices

24 product recalls in 22 recall events; 24 initiated in the last five years and 24 still open. Most recent: 2026-09-23.

YearRecalls
20221
20232
20241
20258
202612

HCPCS codes with matching descriptors

Text match between the FDA device name and CMS descriptors, not an official crosswalk:

Frequently asked questions

What is FDA product code QFG?

QFG is the FDA product code for alternate controller enabled insulin infusion pump. It is a Class II device, regulated under 21 CFR 880.5730 and reviewed by the Clinical Chemistry panel.

What device class is QFG?

Class II, regulation 21 CFR 880.5730. Typical premarket route: 510(k).

How long does a 510(k) take for product code QFG?

Across 29 cleared submissions the average was 165 days from receipt to decision (median 97).

Which companies have the most QFG clearances?

Tandem Diabetes Care, Inc. (9); Beta Bionics, Inc. (6); Deka Research and Development (4); Medtronic Minimed, Inc. (3); Insulet Corporation (3).

Have QFG devices been recalled?

Yes: 24 product recalls across 22 recall events; the most recent began 2026-09-23.

Next steps

Compiled by Caduvo from public U.S. FDA records. Applicant names are shown as FDA records them. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA. Not regulatory advice. Report an error. Data and corrections policy.

All Clinical Chemistry product codes · FDA product code lookup · 510(k) database search · 510(k) review times